HnF4alpha dysfunction as a molecular rational for cyclosporine induced hypertension

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Niehof, Monika ^a   Borlak, Jürgen ^a,b  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSINOGEN; CAPTOPRIL; CYCLOSPORIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; RENIN; TRANSCRIPTION FACTOR NFAT; HEPATOCYTE NUCLEAR FACTOR 4; HNF4A PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BIOINFORMATICS; CELL STRAIN HEPG2; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA BINDING; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HYPERTENSION; INHIBITION KINETICS; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VASOCONSTRICTION; BINDING SITE; BIOLOGY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LIVER CELL CARCINOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANGIOTENSIN II; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; CONSENSUS SEQUENCE; CYCLOSPORINE; GENE EXPRESSION REGULATION; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; NFATC TRANSCRIPTION FACTORS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; TRANSCRIPTION, GENETIC;

EID: 79551520267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016319     Document Type: Article

References (57)

1. Mason J (1990) The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr Nephrol 4: 554-574.
2. Luke RG (1991) Mechanism of cyclosporine-induced hypertension. Am J Hypertens 4: 468-471.
3. Singer DR, Jenkins GH (1996) Hypertension in transplant recipients. J Hum Hypertens 10: 395-402.
4. Heisel O, Heisel R, Balshaw R, Keown P (2004) New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 4: 583-595.
5. Robert N, Wong GW, Wright JM (2010) Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev CD007893.
6. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, et al. (2000) Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 101: 2863-2869.
7. Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, et al. (2003) Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 42: 754-760.
8. Bartholomeusz B, Hardy KJ, Nelson AS, Phillips PA (1998) Modulation of nitric oxide improves cyclosporin A-induced hypertension in rats and primates. J Hum Hypertens 12: 839-844.
9. Grobecker HF, Riebel K, Wellenhofer T (1995) Cyclosporine A-induced hypertension in SHR and WKY: role of the sympatho-adrenal system. Clin Exp Pharmacol Physiol Suppl 22: S94-S95.
10. Rolls KA, Phillips PA, Aldred K, Hardy KJ (1994) Vasoconstrictor responses to components of the renin-angiotensin system in cyclosporin-induced hypertension in the rat. Clin Exp Pharmacol Physiol 21: 227-230.
11. Morgan BJ, Lyson T, Scherrer U, Victor RG (1991) Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats. Hypertension 18: 458-466.
12. Rego A, Vargas R, Cathapermal S, Kuwahara M, Foegh ML, et al. (1991) Systemic vascular effects of cyclosporin A treatment in normotensive rats. J Pharmacol Exp Ther 259: 905-915.
13. Carrier M, Tronc F, Stewart D, Pelletier LC (1991) Dose-dependent effect of cyclosporin on renal arterial resistance in dogs. Am J Physiol 261: H1791-H1796.
14. Tronc F, Carrier M, Pelletier LC (1991) [Effect of therapeutic doses of cyclosporine injected into the renal and femoral arteries in dogs]. Ann Chir 45: 827-832.
15. Tresham JJ, Whitworth JA, Scoggins BA, Bennett WM (1990) Cyclosporineinduced hypertension in sheep. The role of thromboxanes. Transplantation 49: 144-148.
16. Clozel JP, Fischli W, Menard J (1993) Effects of the blockade of the reninangiotensin system in cyclosporin-induced hypertension. J Hypertens 11: 75-81.
17. Cauduro RL, Costa C, Lhulier F, Garcia RG, Cabral RD, et al. (2005) Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients. Clin Transplant 19: 470-474.
18. Lassila M (2002) Interaction of cyclosporine A and the renin-angiotensin system; new perspectives. Curr Drug Metab 3: 61-71.
19. Ventura HO, Malik FS, Mehra MR, Stapleton DD, Smart FW (1997) Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 12: 375-381.
20. Shang MH, Yuan WJ, Zhang SJ, Fan Y, Zhang Z (2008) Intrarenal activation of renin angiotensin system in the development of cyclosporine A induced chronic nephrotoxicity. Chin Med J (Engl) 121: 983-988.
21. Edwards BD, Chalmers RJ, O'Driscoll JB, Mitchell DM, Smith RJ, et al. (1994) Angiotensin II as a risk factor for cyclosporin nephrotoxicity in patients with psoriasis. Clin Nephrol 41: 350-356.
22. Julien J, Farge D, Kreft-Jais C, Guyene TT, Plouin PF, et al. (1993) Cyclosporine-induced stimulation of the renin-angiotensin system after liver and heart transplantation. Transplantation 56: 885-891.
23. Letizia C, d'Ambrosio C, De Ciocchis A, Scavo D, Pozzilli P (1995) Serum angiotensin-converting enzyme levels in patients with recent-onset insulindependent diabetes after one year of low-dose cyclosporin therapy. IMDIAB Study Group. Int J Clin Pharmacol Res 15: 209-213.
24. Erman A, Chen-Gal B, Zabludowski J, Rosenfeld JB (1990) Cyclosporin A treatment enhances angiotensin converting enzyme activity in lung and serum of rats. J Pharm Pharmacol 42: 525-527.
25. Wu MS (2007) From bedside to bench drug-induced tubulointerstitial disease cyclosporine nephropathy study from models of cultured renal epithelial cells. Chang Gung Med J 30: 7-16.
26. Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktionova SA, Lhote P, et al. (1999) Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 55: 2407-2414.
27. Regitz-Zagrosek V, Auch-Schwelk W, Hess B, Klein U, Duske E, et al. (1995) Tissue- and subtype-specific modulation of angiotensin II receptors by chronic treatment with cyclosporin A, angiotensin-converting enzyme inhibitors and AT1 antagonists. J Cardiovasc Pharmacol 26: 66-72.
28. Iwai J, Kanayama Y, Inoue NN, Okamura M, Takeda T (1993) Increased endothelial gene expression of angiotensin AT1A receptor in cyclosporine induced hypertensive rats. Eur J Pharmacol 248: 341-344.
29. Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, et al. (1988) The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 33: 590-600.
30. Bantle JP, Boudreau RJ, Ferris TF (1987) Suppression of plasma renin activity by cyclosporine. Am J Med 83: 59-64.
31. Mason J, Muller-Schweinitzer E, Dupont M, Casellas D, Mihatsch M, et al. (1991) Cyclosporine and the renin-angiotensin system. Kidney Int Suppl 32: S28-S32.
32. Ramirez C, Olmo A, O'Valle F, Masseroli M, Aguilar M, et al. (2000) Role of intrarenal endothelin 1, endothelin 3, and angiotensin II expression in chronic cyclosporin A nephrotoxicity in rats. Exp Nephrol 8: 161-172.
33. Young BA, Burdmann EA, Johnson RJ, Alpers CE, Giachelli CM, et al. (1995) Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 48: 439-448.
34. Busauschina A, Schnuelle P, van der Woude FJ (2004) Cyclosporine nephrotoxicity. Transplant Proc 36: 229S-233S.
35. Moser M (2007) Hypertension treatment guidelines: is it time for an update? J Clin Hypertens (Greenwich) 9: 9-14.
36. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, et al. (2006) Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17: 889-899.
37. Borlak J, Niehof M (2009) HNF4alpha and HNF1alpha dysfunction as a molecular rational for cyclosporine induced posttransplantation diabetes mellitus. PLoS ONE 4: e4662.
38. Yanai K, Hirota K, Taniguchi-Yanai K, Shigematsu Y, Shimamoto Y, et al. (1999) Regulated Expression of Human Angiotensinogen Gene by Hepatocyte Nuclear Factor 4 and Chicken Ovalbumin Upstream Promoter-Transcription Factor. J Biol Chem 274: 34605-34612.
39. Shimamoto Y, Ishida J, Yamagata K, Saito T, Kato H, et al. (2004) Inhibitory effect of the small heterodimer partner on hepatocyte nuclear factor-4 mediates bile acid-induced repression of the human angiotensinogen gene. J Biol Chem 279: 7770-7776.
40. Richer C, Giroux B, Plouin PF, Maarek B, Giudicelli JF (1984) Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. Br J Clin Pharmacol 17: 243-250.
41. Anderson N, Meier T, Borlak J (2009) Toxicogenomics applied to cultures of human hepatocytes enabled an identification of novel petasites hybridus extracts for the treatment of migraine with improved hepatobiliary safety. Toxicol Sci 112: 507-520.
42. Niehof M, Borlak J (2009) Expression of HNF4alpha in the human and rat choroid plexus: implications for drug transport across the blood-cerebrospinalfluid (CSF) barrier. BMC Mol Biol 10: 68.
43. Curnow KM (1996) Human type-1 angiotensin II (AT1) receptor gene structure and function. Clin Exp Pharmacol Physiol Suppl 3: S67-S73.
44. Elton TS, Martin MM (2003) Alternative splicing: a novel mechanism to finetune the expression and function of the human AT1 receptor. Trends Endocrinol Metab 14: 66-71.
45. Kel A, Reymann S, Matys V, Nettesheim P, Wingender E, et al. (2004) A novel computational approach for the prediction of networked transcription factors of aryl hydrocarbon-receptor-regulated genes. Mol Pharmacol 66: 1557-1572.
46. Li C, Lim SW, Sun BK, Yang CW (2004) Chronic cyclosporine nephrotoxicity: new insights and preventive strategies. Yonsei Med J 45: 1004-1016.
47. Shehata M, el Nahas M, Barkworth E, Cope GH, Raftery AT (1995) Localization of PDGF-BB in the juxtaglomerular cells of cyclosporin-treated rats. Exp Nephrol 3: 173-179.
48. Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, et al. (1995) Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 6: 1186-1196.
49. Wolf G, Thaiss F, Stahl RA (1995) Cyclosporine stimulates expression of transforming growth factor-beta in renal cells. Possible mechanism of cyclosporines antiproliferative effects. Transplantation 60: 237-241.
50. Varagic J, Frohlich ED (2002) Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol 34: 1435-1442.
51. Heit JJ, Apelqvist AA, Gu X, Winslow MM, Neilson JR, et al. (2006) Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 443: 345-349.
52. Jamaluddin M, Meng T, Sun J, Boldogh I, Han Y, et al. (2000) Angiotensin II induces nuclear factor (NF)-kappaB1 isoforms to bind the angiotensinogen gene acute-phase response element: a stimulus-specific pathway for NF-kappaB activation. Mol Endocrinol 14: 99-113.
53. Porrello ER, Delbridge LM, Thomas WG (2009) The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci 14: 958-972.
54. Keidar S, Kaplan M, Gamliel-Lazarovich A (2007) ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 73: 463-469.
55. Batlle D, Soler MJ, Wysocki J (2008) New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy. Curr Opin Nephrol Hypertens 17: 250-257.
56. Oudit GY, Crackower MA, Backx PH, Penninger JM (2003) The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 13: 93-101.
57. Bai JP, Lesko LJ, Burckart GJ (2010) Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors. Pharmacotherapy 30: 195-209.